On September 2, 2022, after considering all strategic alternatives, Allena Pharmaceuticals, Inc. filed a voluntary petition for relief under the provisions of Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware. The bankruptcy case is being administered under the caption In re Allena Pharmaceuticals, Inc. (Case No. 22-10842).

In connection with this Chapter 11 filing, the Company has appointed Matthew Foster as the Company's Chief Restructuring Officer, effective as of September 2, 2022. In connection with the Chapter 11 filing, on September 2, 2022, the Company terminated the employment of substantially all of its employees, including Louis Brenner, President. As previously disclosed, in January 2022 the Company entered into retention agreements with each of Dr. Brenner and Dr. Katz as a result of which no additional severance payments will be provided in connection with these separations.

In connection with such retention agreements, each executive agreed to provide three months of consulting services to the Company, as requested by the Company, at an hourly rate derived using the executive officer's current base salary. In addition, on September 2, 2022 and following approval of the Chapter 11 filing and related actions, Louis Brenner, Gino Santini and Allene Diaz resigned from the Board of Directors (the “Board”) of the Company, effective as of the filing of the Voluntary Petition with the Court. At the time of resignation, Ms. Diaz was Chair of the Compensation Committee and a member of the Nominating and Corporate Governance Committee of the Board and Mr. Santini was a member of the Audit Committee and the Compensation Committee of the Board.

The resignations are not the result of any disagreement with the Company regarding the Company's operations, policies or practices.